GlassScriptPhysician profile
Kenneth Mark Ellner
NPI 1447259577
$10,195.46
in general payments reported to CMS, 2019-2025
30 companies · $1,408 in 2025
The $1,408 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,208 · 2020: $673 · 2021: $1,906 · 2022: $1,424 · 2023: $1,835 · 2024: $1,742 · 2025: $1,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,701 · Education: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,701.49 |
| Education | $282.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,689.32 | 2019-2025 | |
| Merz North America, INC. | $1,392.71 | 2019-2022 | |
| Pfizer INC. | $987.41 | 2019-2025 | |
| Janssen Biotech, INC. | $631.44 | 2019-2025 | Tremfya, Simponi, Stelara |
| Incyte Corporation | $451.67 | 2021-2025 | Opzelura |
| Amgen INC. | $451.66 | 2020-2025 | Otezla, Otezla |
| Lilly USA, LLC | $408.68 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $403.42 | 2022-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $372.77 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $299.49 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $266.91 | 2021-2025 | |
| Ucb, INC. | $265.05 | 2020-2025 | Bimzelx |
| Genzyme Corporation | $246.92 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $228.29 | 2020-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $220.51 | 2019-2025 | Adbry, Anzupgo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $151.21 | 2020-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $126.21 | 2019-2023 | Ilumya |
| Organon LLC | $121.10 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $117.63 | 2020-2025 | Jublia |
| Botanix Sb INC | $85.13 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.57 | 2024-2025 | Spevigo |
| Epi Health, LLC | $42.70 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $30.65 | 2019-2023 | |
| Almirall LLC | $26.80 | 2024 | Klisyri |
| Springworks Therapeutics, INC. | $24.51 | 2025 | Gomekli |
| Lnhc, INC | $23.58 | 2025 | Zelsuvmi |
| Dermira, INC. | $21.18 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.61 | 2024 | Simlandi |
| Sanofi-Aventis U.S. LLC | $17.15 | 2021 | |
| Celgene Corporation | $14.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Ellner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.